Results 111 to 120 of about 11,456 (188)

Dapagliflozin Attenuates NKCC2 Protein Expression and Alleviates Diabetic Kidney Disease in Salt Loaded‐Hypertensive Diabetic Db/Db Mice

FASEB BioAdvances, Volume 8, Issue 10, October 2026.
In salt‐loaded, hypertensive diabetic db/db mice with diabetic kidney disease, dapagliflozin lowered blood pressure and reduced tubular and glomerular injury. Mechanistically, dapagliflozin increased cullin E3 ligase abundance, promoting degradation of NKCC2.
Zenab Shahzad, Niharika Bala, Arooba Illyas, Amir Kazory, Indra Chandrasekar, Abdel A. Alli   +5 more
wiley   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Effect of sodium‐glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin‐treated diabetic dogs

Journal of Veterinary Internal Medicine
Background The utility of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) has not been reported in insulin‐treated diabetic dogs. Hypothesis Canagliflozin, a PO‐administered SGLT2i, decreases interstitial glucose concentration (IG) in insulin‐treated ...
Jessica R. Box, Mark A. Oyama, Ariel S. Mosenco, Rebecka S. Hess   +3 more
doaj   +1 more source

SGLT2 Inhibitor Use in Type 2 Diabetes in England: A Population‐Based Cross‐Sectional Study of Uptake of NICE Guidance

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9573-9583, October 2026.
ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller, Jonathan Wray, Muksitur Rahman, James Hawkins, Chirag Bakhai, Daniel J. Cuthbertson, Robert Willans, Eleanor Yelland, Shaun Rowark, Magdalena Watras, Luke Sheridan Rains, Amanda I. Adler, Lesley Owen   +12 more
wiley   +1 more source

Real‐world risk factors and clinical implications of early estimated glomerular filtration rate decline after sodium‐glucose cotransporter‐2 inhibitor therapy

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1735-1743, October 2026.
Older age, atrial fibrillation, loop diuretic use, and higher eGFR variability predicted early eGFR dip. Continued SGLT2 inhibitor therapy preserved long‐term kidney function, although closer monitoring is warranted in patients receiving loop diuretics. ABSTRACT Aim To assess the prevalence, risk factors, estimated glomerular filtration rate trajectory,
Jangwook Lee, Dayoung Kang, Kyoung‐Ah Kim, Han Seok Choi, Soomin Jo, Joeun Kim, Jae Yoon Park, Seung Eun Lee   +7 more
wiley   +1 more source

Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study

BMC Endocrine Disorders
Background While the Sodium-glucose co-transporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) are widely used for the glycemic control in type 2 diabetes mellitus, the differences in the effects of SGLT2 inhibitors and DPP4 inhibitors on ...
Masahiro Isogawa, Hisashi Makino, Cheol Son, Kunihiro Nishimura, Takumi Hirata, Shu Kasama, Yoshihiro Miyamoto, Michio Noguchi, Masato Kasahara, Kiminori Hosoda   +9 more
doaj   +1 more source

The Effect of Canagliflozin on High-Density Lipoprotein Cholesterol and Angiopoietin-Like Protein 3 in Type 2 Diabetes Mellitus

Journal of Diabetes Research
Background. Diabetes mellitus is often accompanied by dyslipidemia. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, as a novel therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), have been reported to exert effects on lipid, while ...
Simo Liu, Jing Ke, Xiaotong Feng, Zongwei Wang, Xin Wang, Longyan Yang, Dong Zhao   +6 more
doaj   +1 more source

Canagliflozin‐induced renal glutathione distribution mapping in non‐diabetic male rat kidneys

Physiological Reports
Canagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, has direct renoprotective effects beyond lowering blood glucose levels. The inhibition of sodium reabsorption via SGLT2 reduces the overload on proximal tubules, thereby suppressing the ...
Guy Watanabe, Shoichiro Horita, Reika Flora Moriya, Yusuke Masuishi, Shingen Misaka, Shu Taira, Kenju Shimomura, Michio Shimabukuro, Junichiro James Kazama   +8 more
doaj   +1 more source

Dual Roles of Canagliflozin on Cholangiocarcinoma Cell Growth and Enhanced Growth Suppression in Combination with FK866

Cholangiocarcinoma-associated mortality has been increasing over the past decade. The sodium-glucose cotransporter 2 inhibitor, canagliflozin, has demonstrated anti-tumor effects against several types of cancers; however, studies examining its potential ...
Yohei Shirakami, Ibuka, Takashi, Shimizu, Masahito, Taguchi, Daisuke, Takao Miwa, Maeda, Toshihide, Kubota, Masaya, Minowa, Daisuke, Daisuke Minowa, Hiroyasu Sakai, Masaya Kubota, Takashi Ibuka, Imai, Kenji, Shirakami, Yohei, Kenji Imai, Miwa, Takao, Masahito Shimizu, Sakai, Hiroyasu, Daisuke Taguchi, Toshihide Maeda   +19 more
core   +1 more source

Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis. [PDF]

BMJ Open
Aladul MI, Hijazeen RA, Al-Shammaa ZM.
europepmc   +1 more source